The Critical Importance of Early Treatment in Hidradenitis Suppurativa
Experts emphasize the need for prompt intervention in Hidradenitis Suppurativa to prevent severe complications and improve patient quality of life.
Early treatment can prevent progression and reduce surgical needs in Hidradenitis Suppurativa.
Patients often experience significant fatigue and pain, impacting their daily lives.
Biologics are effective in about 60% of cases, but timely intervention is crucial.
Dr. Hamzavi highlighted the significance of early intervention in Hidradenitis Suppurativa (HS), a condition that can escalate from painful nodules to complex sinus tunnels leading to chronic drainage and severe tissue damage. The primary goal of early treatment is to halt this progression, thereby preventing scarring and the formation of tunnels, which can significantly impact a patient's quality of life by reducing the days lost to pain and inflammation.
The progression of HS is concerning, as noted by Dr. Hamzavi, who referenced research indicating that once sinus tunnels become inflamed, the inflammatory infiltrate changes, potentially increasing the extent of surgical intervention required. This underscores the importance of treating HS early to mitigate the surgical burden on patients, who may face more extensive procedures if treatment is delayed.
Dr. Hamzavi pointed out that many critical patient outcomes, such as fatigue and the speed of response to treatment, are often overlooked in clinical trials. Patients suffering from HS frequently report debilitating fatigue, which can severely affect their daily activities. He emphasized that for those enduring severe pain, the urgency of treatment is paramount, stating that waiting months for relief is unacceptable.
The efficacy of biologics in treating HS is notable, with approximately 60% of patients responding positively under optimal conditions. However, determining the right advanced therapy at the appropriate time remains a significant challenge for healthcare providers. The decision-making process regarding the addition of other treatments also requires careful consideration to ensure the best outcomes for patients.
Looking ahead, the medical community is urged to prioritize early treatment strategies for Hidradenitis Suppurativa to enhance patient outcomes. Upcoming discussions and research presentations, such as those scheduled for the Fall Clinical Dermatology Conference in October 2026, will further explore these critical issues and aim to refine treatment protocols for HS.
